No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.

CONCLUSION: Decreased SMI during neoadjuvant chemotherapy was not associated with worse outcome in patients with stage III ovarian cancer included in the OVHIPEC-trial. However, a strong association between decreasing SMI and adverse events was found.
PMID: 33019981 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - October 1, 2020 Category: Cancer & Oncology Authors: Ubachs J, Koole SN, Lahaye M, Fabris C, Bruijs L, Schagen van Leeuwen J, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham M, van Dam P, Vuylsteke P, Bastings J, Kruitwagen RFPM, Lambrechts S, Olde Damink SWM, Rensen SS, Van Gorp Tags: Gynecol Oncol Source Type: research